Post-earnings recap
Reported
Thu, Apr 23, 2026
EPS actual
$5.44
EPS est.
$5.20
EPS surprise
+4.68%
1-day move
-9.20%
Thermo Fisher Scientific's earnings report showed a positive surprise in EPS, indicating better-than-expected profitability. However, the stock reaction remained flat, suggesting that investors may be cautious or awaiting further details on revenue performance and future guidance. The lack of revenue data and guidance may lead to uncertainty in the market moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $5.44 | N/A | +4.68% |
| Revenue | N/A | N/A | N/A |
Overall, management expressed confidence in the company's strategic direction while acknowledging market challenges. They noted positive trends in customer demand.
Management highlighted strong demand in key segments.
They emphasized ongoing investments in innovation.
There was a focus on maintaining operational efficiency.
Thermo Fisher Scientific (TMO) is a leading company in the health care sector, specializing in life sciences tools and services. Their products and services are critical for laboratories and research facilities, making them a key player in advancements in health care and scientific research.
Last quarter
In Q4 2025, Thermo Fisher reported an EPS of $6.57, exceeding estimates by 2.13%. However, the stock saw a decline of 2.61% the following day, indicating mixed market reactions.
Management promises and guidance
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+3.14%
Avg 1-day reaction
+1.51%
Overall expectations for Thermo Fisher's upcoming earnings are cautious, given the lack of specific guidance and mixed reactions to previous results.
Bull case
If the company can deliver strong EPS and revenue growth, it may signal robust demand for its products, leading to positive market sentiment.
Bear case
Conversely, any signs of slowing growth or margin compression could lead to a negative reaction from investors, especially given the recent stock performance.
The print will turn on these.
Q1
What will the EPS be this quarter, and how does it compare to previous quarters?
Given the company's track record of beating EPS estimates, this figure will be crucial in determining market sentiment.
Q2
What are the expectations for revenue growth in key segments?
Understanding revenue growth in critical areas will help assess the company's market position and future prospects.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Why consensus could be wrong
The Street may underestimate the potential for revenue growth in emerging markets, which could significantly boost overall performance.
Supporting evidence
Previous quarters have shown consistent EPS beats, indicating stronger underlying demand than anticipated.
Options pricing suggests a larger move than historical averages, hinting at potential surprises.
The company's commitment to innovation could drive unexpected revenue streams.
Key risk
If revenue growth exceeds expectations, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
The market is closely watching EPS and revenue growth, as these metrics will indicate the company's health and future direction.
Bull confirmed if
An EPS of $6.80 or higher would confirm strong performance and growth.
Bear confirmed if
An EPS below $6.30 could signal potential challenges in maintaining profitability.
What the market is pricing for the move.
Implied Move
±4.47%
Historical Avg
±5.1%
The options market is pricing in a significant move, suggesting that traders anticipate volatility around the earnings report.
Options are pricing ±4.5% while TMO has averaged ±5.1% over the last 8 prints — setup is roughly in line with history.
30d HV
31.7%
Smart-money positioning from the most recent 13F filings.
Institutional
94.08%
of float
Insider
0.13%
of float
Holders
3,552
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
30,919,632 sh · $20.5B
8.36%
1.6%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Thermo Fisher beats expectations, history suggests a potential stock increase of around +2.14%, confirming strong demand.
In line / cautious
If results are in line with expectations, the stock may see muted movement as investors await further guidance.
Miss
A miss could lead to a decline, with historical patterns indicating an average drop of around -0.71%.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
2
0 buys·2 sells
Members
2
House only
Est. Notional
$2,002.00–$30,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Vanguard Capital Management LLC
24,276,316 sh · $16.1B
6.57%
-0.0%
State Street Corporation
16,825,879 sh · $11.1B
4.55%
0.6%
FMR, LLC
14,084,488 sh · $9.3B
3.81%
30.7%
Morgan Stanley
10,763,066 sh · $7.1B
2.91%
-0.9%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net selling
1 trade
Net selling
Recent Transactions
Traded Jul 10, 2026 · disclosed Jul 17, 2026
$1,001.00–$15,000.00
Traded May 7, 2026 · disclosed May 15, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.